Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- How Its Bold Acquisition Made Schering a Takeover Target
- "The promise of this combination is profound," CEO Fred Hassan said when Schering bought Organon in March 2007. That proved true, but in a way that no one -- not even Hassan -- anticipated at the time. by Cait Murphy
- Articles 2010-01-27
- The Side-Effects of a Giant Merger
- Morningstar healthcare industry analyst Damien Conover explains the fallout from Schering's $14 billion purchase of Organon in 2007. by Damien Conover, as told to Cait Murphy
- Articles 2010-01-27
Additional Resources
- Drawing data from the same well. (interview with Merck treasurer Caroline Dorsa)(includes related article on use of Internet in corporate treasury department)(Treasury Management)(Interview)
- Merck Treas. Caroline Dorsa claims that the revamp of the treasury department's finance and management information systems was prompted by the desire to keep the finance function relevant to the company's other business units. The finance department needeMerck Treas. Caroline Dorsa claims that the revamp of the treasury department's finance...
- Research articles 1996-09-01
- Merck completes generics acquisition. (Business & Finance News).(Merck KgaA buys generic drugs maker Mohan Medicine Research Institute)(Brief Article)
- Merck KgaA has completed the acquisition of generic drugs company Mohan Medicine Research Institute Tokyo from Kyowa Hakko Kogyo. The deal raises Merck's generics sales in Japan to [euro]1.20 million($109 million)/year and makes it the third-biggest supplier there.
- Research articles 2002-03-20
- Chemical firms post mixed pharmaceutical earnings. (Finance).(Bayer, Akzo Nobel, Merck KGaA)(Brief Article)(Statistical Data Included)
- Bayer, Akzo Nobel, and Merck KGaA posted contrasting first-quarter results for their pharmaceuticals businesses table. Akzo and Merck both reported profit gains, but Bayer's business was off dramatically. Sales and profits in Bayer's pharmaceuticals division fell due to the withdrawal last year of...
- Research articles 2002-05-08
- Shomex Says Exhibitors Up 40% At Workforce Diversity Expo; 50 Major Employers Including BAE Systems, FBI, Harvard University, KeyBank, Intel And Merck Will Be Looking For New Talent
- BOSTON -- Shomex, a national event producer and the leader in live recruitment solutions, announced today a preliminary list of companies that will be exhibiting at its Diversity Career Fair, presented in partnership with BostonWorks, a division of The Boston Globe, on June 21, 2005 at the Hynes Convention Center....
- Research articles 2005-06-16
- UK pain as animal rights fear stalks big pharma; CITY&FINANCE
- Byline: IAN LYALL ANIMAL rights extremists are threatening the long-term health of British drugs research. giants such as GlaxoSmithKline, AstraZeneca and Merck are already exporting research and development jobs to low-cost regions such as South America, India and China and militant campaigners are giving them an...
- Research articles 2004-11-16
- ImClone Systems Inc. Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator [Operator Instructions]. Your first question comes from May-Kin Ho of Goldman Sachs. May-Kin Ho - Goldman Sachs Hi. I guess, I wanted to ask question about really how your payment from Bristol would be recognized and how we should going forward project out...
- Earnings calls 2007-10-25
- Merck-Schering Roundup: Layoffs More Likely at Schering; Insiders Traded Fortuitously; How Merck Timed the Deal
- LAYOFFS? In the Merck/Schering-Plough merger, layoffs will likely fall most heavily on the Schering employees. This is not just because Merck is the acquiring company and will place its people in the driving seats. (That, of course, will be part of it.) Rather, it's because Schering has...
- Blog posts 2009-03-10
- Merck-Schering: SEC Launches Insider Trading Probe
- The SEC has launched an insider trading probe around Schering-Plough and its March merger agreement with Merck, according to the WSJ. Stock in SGP jumped 8 percent on Friday March 6; the merger was announced on Monday March 9. This graphic shows that on Thursday, SGP stock...
- Blog posts 2009-04-30
- Need to know: Electrolux cut ... Merck consent ... Cape success
- View video and Need to Know interactive heatmap Economics UK economy: Britain is now in the grip of the longest recession on record, according to official data. The economy shrank 0.4 per cent between July and September, its sixth consecutive quarterly decline. Output has fallen 5.9 per cent since the...
- News items 2009-10-23
- Merck Provides Update on Merger Financing
- WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today provided an update on the status of credit facilities that will be used to finance its recently announced agreement to...
- Research articles 2009-03-23
- Texas Pacific in running for Merck's generics business
- FRANKFURT AFP — US finance company Texas Pacific Group is interested in buying the generic drugs activities of German pharmaceuticals specialist Merck KGaA, a newspaper has reported. Texas Pacific, a private equity firm, wanted to make an offer alone rather than jointly with other private equity investors, the Handelsblatt said...
- Research articles 2007-01-12
- Statement by Dr. Steven Galson, Acting Director, Center for Drug Evaluation and Research (CDER), regarding November 18, 2004, Committee on Finance of the U.S. Senate Hearing on Drug Safety and the Worldwide Withdrawal by Merck & Co., Inc., of Vioxx.
- M2 PRESSWIRE-19 November 2004-US FDA: Statement by Dr. Steven Galson, Acting Director, Center for Drug Evaluation and Research CDER, regarding November 18, 2004, Committee on Finance of the U.S. Senate Hearing on Drug Safety and the Worldwide Withdrawal by Merck & Co., Inc., of VioxxC1994-2004 M2...
- Research articles 2004-11-19
- Merck confirms examining possible sale of generic drugs business
- DARMSTADT, Germany AFP — Merck KGaA, the German pharmaceuticals and specialty chemicals maker, confirmed that it was considering selling its generic drugs business in a move that could help finance its acquisition of Swiss drug maker Serono. "We are evaluating the divestiture of our generics division as one strategic option,"...
- Research articles 2007-01-05
- Merck's top finance officer to retire
- Continuing the post-Vioxx makeover, Merck & Co. Inc.'s chief financial officer and onetime heir apparent, Judy Lewent, will take early retirement this summer, the company said yesterday. Lewent, 58, who has been credited with helping Merck regain its financial footing after the 2004 recall of its blockbuster pain reliever...
- Research articles 2007-02-21
- Salix Pharmaceuticals of Raleigh has entered into a credit facility with Bank of America for up to $100 million to help finance the purchase of two drugs from Merck & Co. and for working capital, capital expenditures, other acquisitions and general co
- Salix Pharmaceuticals of Raleigh has entered into a credit facility with Bank of America for up to $100 million to help finance the purchase of two drugs from Merck & Co. and for working capital, capital expenditures, other acquisitions and general corporate purposes. Salix has borrowed about $15 million thus...
- Research articles 2007-03-01
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Merck to triple liquid crystals; seeks electronic chemicals partner. (Business & Finance News: Europe/Mideast).
- Merck KGaA says it needs to expand its liquid crystal capacity "significantly" to meet strong demand. The expansion would be in addition to the [euro]125-million ($125 million) plant at Darmstadt, Germany that the company will complete in 2005. That plant will make active pharma ingredients and...
- Research articles 2002-11-06
- << Previous
- page 1 of 1
- Next >>
